We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Method Identifies Anthrax Bacteria Faster Than Current Approaches

By LabMedica International staff writers
Posted on 06 Mar 2014
A new method has been developed for rapid diagnostic detection and antibiotic susceptibility determination of the pathogenic Bacillus anthracis using a bioluminescent reporter phage.

Although anthrax is a treatable disease, positive patient prognosis is dependent on rapid diagnosis and therapy. More...
A team at the University of Missouri (MU; Columbia, MO, USA) assessed a bioluminescent reporter phage, developed by David Schofield at Guild BioSciences (Charleston, SC, USA), for its value as a clinical diagnostic tool for Bacillus anthracis. The reporter phage based method, published in the Journal of Microbiological Methods (November 2013), detects live B. anthracis strains by transducing a bioluminescent phenotype. It was found to rule out false positives – displaying species specificity by its inability, or significantly reduced ability, to detect members of the closely related Bacillus cereus group and other common bacterial pathogens.

The method detects low levels of B. anthracis, at clinically relevant bacterial concentrations, within 5 hours. “Normally to identify whether an organism is present, you have to extract the material, culture it, and then pick colonies to examine that might turn out to be anthrax bacteria,” said Prof. George Stewart, PhD, medical bacteriologist. “Then you conduct chemical testing which takes some time—a minimum of 24 to 48 hours. Using this newly-identified method, we can reduce that time to about 5 hours.” The method also provides antibiotic susceptibility information that mirrors the CLSI method, except that data are obtained at least 5-fold faster.

In addition to saving lives, the new method could also save on high clean up and decontamination costs of bioterrorism attacks. These costs for the post-9/11 2001 anthrax letters attack totaled USD 3.2 million, according to a 2012 report. “In the years since the post-9/11 postal attacks, we haven’t had any bona fide anthrax attacks,” said Prof. Stewart; “That doesn’t mean that it’s not going to happen, we just have to be prepared.” Current methods take 1–3 days to produce definitive results for anthrax. The new detection method would potentially alert of a negative result 5 hours into clean-up efforts instead of 1–3 days into expensive decontamination.

Related Links:
University of Missouri at Columbia
Guild Biosciences


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.